Multicentric EORTC retrospective study shows efficacy of brentuximab vedotin in patients who have mycosis fungoides and Sézary syndrome with variable CD30 positivity.

E PapadavidEirini KapniariV PappaVasiliki A NikolaouT IliakisMaria DalamagaC JonakS PorkertS EngelinaPietro Quaglino Pablo Luis Ortiz-Romero Cristina Vico-AlonsoA CozzioFlorentia DimitriouR GuironEmmanuella GuenovaE HodakMartine Bagot Julia J Scarisbrick

Published in: The British journal of dermatology (2021)

BV is an effective option for patients with MF/SS, including those with variable CD30 positivity, large-cell transformation, SS, longer disease duration and who have been treated previously with several therapies.

Keyphrases

newly diagnosed
end stage renal disease
ejection fraction
hodgkin lymphoma
single cell
prognostic factors
peritoneal dialysis
stem cells
cell therapy
nk cells
patient reported outcomes
mesenchymal stem cells
inflammatory response